

PCT

WORLD INTELLECTUAL PR
Internations

INTERNATIONAL APPLICATION PUBLISHED UND



(51) International Patent Classification ⁶ :	A2	(11)	WO 9609038A2
A61K 31/00, 31/195, 31/40, 31/557, 31/68		(43) International Publication Date:	28 March 1996 (28.03.96)
(21) International Application Number:	PCT/GB95/02249		
(22) International Filing Date:	22 September 1995 (22.09.95)		
(30) Priority Data:	2,132,690 22 September 1994 (22.09.94) CA		
(71) Applicant (for all designated States except US):	WILLIAM HARVEY RESEARCH LIMITED [GB/GB]; Saint Bartholomew and the Royal London Hospital School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ (GB).		
(72) Inventors; and			
(75) Inventors/Applicants (for US only):	WILLIS, Dean [GB/GB]; 16 Croft Road, Atherstone, Warwickshire CV9 1HQ (GB). MOORE, Adrian, Richard [GB/GB]; 101 Windsor Road, Ilford, Essex IG1 1HG (GB). WILLOUGHBY, Derek, Albert [GB/GB]; 83 Bow Lane, Finchley, London N12 0JL (GB).		
(74) Agent:	SCHLICH, George, William; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).		

(54) Title: PHARMACEUTICAL CONTROL OF INFLAMMATION

(57) Abstract

Control of inflammation is achieved by control of the level and/or activity of the enzyme heme-oxygenase (HO). A HO inducer is anti-inflammatory (figure 14) and used to treat inflammation, such as chronic inflammatory diseases. A HO inhibitor promotes inflammation and is used to treat immunosuppressed conditions. Alternative, or additional, control of heme-oxygenase activity is achieved by control of nitric oxide levels, elevated levels promoting inflammation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

Pharmaceutical Control of Inflammation

This invention relates to the control of the inflammatory response, to pharmaceuticals that inhibit or decrease inflammation, to pharmaceuticals that promote, induce or increase inflammation and to treatment of disease states by inhibiting or promoting inflammation. In particular, this invention relates to control of the activity or the amount or both the activity and the amount of heme-oxygenase in the body.

This invention finds in addition to other applications, particular application in the treatment of diseases manifested in or exacerbated by an inflammatory response (such as in the treatment of chronic inflammatory diseases, for example, rheumatoid arthritis), in humans suffering hypersensitivity reactions such as in asthma, in humans suffering conditions in which ROS (Reactive Oxygen Species) have a pathogenic role such as reperfusion injury and atherosclerosis and, in humans having immunosuppressed states resulting from drug treatments or from pathologies such as AIDS.

Chronic inflammatory diseases place a heavy social and economic burden on the resources of many nations, but the number of safe and effective treatments is limited. To date, the major research effort has concentrated on those mediators responsible for the initiation and maintenance of the pathological process. In contrast little attention has been focused on endogenous factors responsible for the resolution of the inflammation.

The main anti-inflammatory pharmaceutical agents are the glucocorticoids and the non-steroidal anti-inflammatory drugs (NSAIDs). Both suffer from well catalogued disadvantages, indeed nearly one quarter of adverse drug reactions reported in the UK are due to NSAIDs. Side-effects of NSAIDs commonly affect the gastrointestinal tract, and also the liver, kidney, spleen, blood and bone marrow. NSAIDs are not effective in treatment of some chronic inflammatory

- 2 -

disorders.

Glucocorticoids are powerful anti-inflammatory agents, suppressing both acute and chronic phases of inflammation. They carry the hazard, however, that they also suppress the immune response and can decrease many aspects of essential cell repair processes. Generally, they must be given by injection and are not effective on oral administration.

There thus exists an on-going need for further anti-inflammatory drugs, which can be given orally and which are effective against chronic inflammation.

Conversely, a number of diseases are known in which there is a significant suppression of the inflammatory response. One example is acquired immune deficiency syndrome (AIDS) in which infection by HIV leads typically to such immuno-suppression that an infected person dies from a separate, opportunistic, infection, often a bacterial or viral infection rarely fatal in a healthy person.

Stimulation or induction of inflammation in this case could assist in preventing death from non-HIV infections. However, no suitable pharmaceutical is known for this pro-inflammatory purpose.

Heme (ferri-protoporphyrin-IX) plays a vital role in cellular metabolism, functioning as the prosthetic group of hemeproteins (eg. hemoglobin and cytochromes). Its catabolism is a two-step process. The first, and rate limiting reaction, is the production of biliverdin and carbon monoxide by the microsomal enzyme heme-oxygenase. The second step is the production of bilirubin from biliverdin by the cytosolic enzyme, biliverdin reductase.

Heme-oxygenase is found in liver, kidney, spleen and skin, and has also been localised to specific cell types, notably fibroblasts and macrophages. The enzyme exists in at least two isoforms, one constitutive and the other inducible. Heme, heavy metal ions (eg. tin, gold, platinum and mercury) and transition metal ions (eg. iron, cobalt, chromium and nickel) can all induce heme-

- 3 -

oxygenase. In addition, heme-oxygenase is induced as part of a generalised stress response to stimuli such as thermal shock (hence the alternative name heat-shock protein 32; hsp32), oxidative stress and cytokines such as interleukin-1 (IL-1), tumour necrosis factor and IL-6. The stress response is seen as beneficial in that it results in protection of vulnerable cell enzymes from inactivation.

Animal biles have been used in traditional Chinese medicine for centuries in the treatment of bronchitis, asthma and other hypersensitivity reactions. More recently, it has been shown that biliverdin and bilirubin scavenge reactive oxygen species (ROS) which can have a range of proinflammatory effects including inactivation of protease inhibitors, depolymerisation of hyaluronic acid to angiogenic fragments and alteration of proteins to give rise to endogenous antigens.

Abraham et al., Int. J. Biochem. 20(6): 543-558 (1988) provides a general review of heme-oxygenase and its role in mammalian physiology including regulation of its activity by endogenous and exogenous factors. The interaction of this enzyme with NADPH-cytochrome P450 reductase is discussed, as is the role of heavy metal ions in inducing heme-oxygenase activity. Metal Porphyrins are taught as inhibitors. At p. 548 of the reference, the author states:

"In general, heme-oxygenase activity increases when cells are under stress or in a disease state. In fact, the enzyme may be regarded as a red light signalling the occurrence of abnormality."

Sacerdoti et al., Science 243: 388-390 (1-20-89) asserts that hypertension was linked to kidney cytochrome P450 levels, and that enzyme could be depleted by inducing heme-oxygenase production. This was done by treatment with Co²⁺.

McCarty (Chemical Abstract. 100: 1864024 (1984)) purports to teach the effect of selenium in reducing leukotrienes which are alleged to be prominent mediators of hyper-sensitivity and inflammation. McCarty, in fact, teaches the

- 4 -

administration of a dietary adjuvant per os.

U.S. Patent No. 5102670 relates to the reduction of ocular swelling by administering a heme-oxygenase inducer to the swollen eye of an individual to increase production of heme-oxygenase to reduce the amount of 12(R) hydroxyeicosatetraenoic acid (12(R)-HETE) present in the eye as well as 12(R) Dihydroxyeicosatrienoic acid (12(R)-DIHETE) also present in the eye. The scheme presented in the patent for reducing corneoconjunctival swelling is thus dependent on the reduction of the arachidonic acid metabolites 12(R)HETE and 12(R)DIHETE found mainly in the eye. In particular, it is explained that the therapeutic effect is primarily on maintaining the blood - aqueous barrier, a barrier not seen other than in the eye. Thus, the teachings in the patent relate solely to the eye and have very little other applicability.

During about the same time period Messrs. George S. Drummond and Hallah Kappas of The Rockefeller University, Drummond, N.Y. were involved together and with others in research relating to heme-oxygenase. The result of the research appears embodied, at least in part, in U.S. Patents No.'s 4657902; 4699903; 4684637; 5010073 and 5223494.

U.S. Patent No. 4657902 purports to teach the use of the novel compound tin mesoporphyrin and compositions containing it to inhibit heme metabolism in mammals, to control the rate of tryptophan metabolism in mammals, and to increase the rate at which heme is excreted by mammals.

The patent disclosure provides as follows at Column 1, lines 22-36:

"In mammals and other vertebrates heme is oxidatively degraded by heme-oxygenase to form the open chain tetrapyrrole biliverdin. In mammals biliverdin is reduced to bilirubin by biliverdin reductase. In liver bilirubin is converted to the mono- and di-glucuronide conjugates by the hepatic glucuronyl transferase system prior to its excretion.

- 5 -

Bilirubin is a toxic compound, but normally this toxicity is not manifest since bilirubin is rapidly bound to plasma proteins, transported to liver, conjugated and excreted. However, in the newborn, high undesirable concentrations of bilirubin exist in serum and may produce neurotoxicity. The intractable neurological syndrome known as "kernicterus" is the most severe manifestation of bilirubin toxicity."

The inventors, therefore, provide at column 3, lines 43-48:

"It has now been discovered that the compound Sn(tin)-mesoporphyrin (SnMP) can be employed in the treatment of mammals including humans in need of such treatment to decrease the rate of heme metabolism, to increase the rate at which heme is excreted and to control the rate of tryptophan metabolism in the liver."

U.S. Patent No. 4699903 purports to teach a method of increasing the rate at which heme is excreted by a mammal in need of increased disposal of heme by administering tin diiododeuteroporphyrin.

U.S. Patent No. 4684637 discloses methods for decreasing the rate of metabolism for decreasing the rate of metabolism of heme in mammals by administration of tin or chromium protoporphyrins IX.

U.S. Patent No. 5010073 purports to relate to liposomal metalloporphyrin preparations for targeting the spleen for inhibition of heme-oxygenase activity in the spleen.

U.S. Patent No. 5223494 purports to teach a method for inhibiting heme-oxygenase activity in the intestine by administering mesoporphyrin for reducing the absorption of iron from foodstuffs by animals in need of such prevention.

- 6 -

This latter group of patents relates to inhibiting heme-oxygenase in selected body tissues by targeting those body tissues (for example, the spleen or intestine) for specified purposes.

Heat shock proteins (HSPs) or stress proteins are a group of proteins that are among the most highly conserved and abundant proteins in the biosphere. Although many of the isoforms of the proteins are expressed under normal physiological conditions and serve vital roles in the cell, they are greatly upregulated by factors which threaten the integrity of the cell. These factors include heat and cold shock, oxygen radicals, heavy metals, hypoxia, infection, ethanol, ionophores and thiol reactive agents. This increase in the cell's concentration of HSPs leads to the cell being transiently resistant to an otherwise lethal insult, and unresponsive to some biological mediators.

The role of HSPs in pathological conditions has attracted much attention. Immune responses to HSPs can be highly cross-reactive and even auto-reactive due to their extensive inter-species amino acid homology. Immune responses to HSPs have already been implicated in adjuvant arthritis in the rat, pristane arthritis in the mouse, diabetes mellitus in the non-obese diabetic mouse, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis and in tumour surveillance. Therefore, it appears that HSPs may have a paradoxical effect in pathological conditions, having a cyto-protective effect on cells and tissue in stressful environments, but eliciting a detrimental immune response in some autoimmune diseases.

Nitric oxide (NO), formed from L-arginine and molecular oxygen by isoforms of the enzyme nitric oxide synthase (NOS EC 1.14.13.39), is involved in a variety of physiological and pathophysiological processes. The reactivity of this molecule and its capacity to complex with metalloproteins, underlies many of its biological actions. For example, activation by NO of heme-containing soluble guanylate cyclase (EC 4.6.1.2) in vascular smooth muscle results in vasoregulation, whilst in host defence, inhibition of iron-sulphur enzymes causes

- 7 -

metabolic dysfunction in invading pathogens.

Inflammation involves the sequential release of various mediators including vasoactive mediators, chemoattractants, cytokines, prostaglandins, free radicals and proteases. In rheumatoid arthritis, a chronic inflammatory disease, HSPs are upregulated in the synovial lining of patients. However, their role in inflammation has yet to be completely elucidated.

Objects of this invention are to provide improved (or at least alternative) means for control of inflammation, in particular treatment of chronic inflammation or stimulation of an inflammatory response, such as in treatment of an immunosuppressed condition.

We have now discovered that by controlling the amount or the activity or both the amount and the activity of heme-oxygenase in the body, either (1) a generalized anti-inflammatory effect or response is obtained wherein heme-oxygenase is induced, or (2) a general inflammatory response is obtained wherein heme-oxygenase is suppressed (or inhibited).

According to one aspect of our invention, inflammation is treated by administration of a compound that induces heme-oxygenase or stimulates or increases the activity of heme-oxygenase. The treatment can be systemic or targeted, for example targeted to an inducible heme-oxygenase found in monocytes and macrophages in the human body. This treatment induces heme-oxygenase production and/or stimulates its activity; specific medical applications include the treatment of chronic inflammatory diseases for example, rheumatoid arthritis, the treatment of hypersensitivity reactions such as in asthma, and, the treatment of injury, atherosclerosis and infarction.

In an embodiment of the invention, a pharmaceutical composition comprises a compound that induces, stimulates or increases the activity of heme-oxygenase, in combination with a pharmaceutically acceptable carrier. The composition is in

- 8 -

the form of a solution for injection, an orally acceptable composition or a topical composition.

A suitable solution for injection includes a sterile, saline-containing solution, preferably containing saline at approximately physiological concentration.

For oral administration, the composition can be in a solid form-such as a tablet, a pill or a powder for suspension in water or for dissolution in water. The preparation of such a solid composition will be known to a person of skill in this art. It is an option to supplement the oral composition with a taste enhancing agent, to make the composition more palatable, or at least less unpleasant by mouth. Suitable taste enhancers includes sweeteners, flavourings and agents that mask or reduce any unpleasant or undesirable taste in the active component of the pharmaceutical.

In the case of a topical composition, the carrier is preferably a non-aqueous carrier adapted to retain the composition in place following application. Suitable carriers include a cream, a gel, a wax, an oil and an emulsion.

The invention thus provides a further anti-inflammatory pharmaceutical. It can be given orally, according to the particular compound chosen, and initial tests have demonstrated useful anti-inflammatory activity. The products of heme-oxygenase are believed to have multiple effects in the progression of inflammation, whereas the products of the enzyme targeted by most NSAIDs, cyclooxygenase, have fewer effects, so the compositions of the invention present a pharmaceutical activity potentially more powerful than that seen in NSAIDs.

Another embodiment of the invention is an anti-inflammatory composition comprising a heme-oxygenase inducer or stimulator and a pharmaceutically acceptable carrier.

A further embodiment of the invention is the use of a compound that induces,

- 9 -

stimulates or increases the activity of heme-oxygenase in the manufacture of a medicament for the treatment of inflammation.

Agents suitable for inducing heme-oxygenase include prostaglandins of the A series; analogues, derivatives, complexes and conjugates of prostaglandins of the A series that are agonists of prostaglandin A receptors; agonists of prostaglandin A receptors; vitamin B₁₂; hemin; and fragments, sub-units, conjugates, analogues, derivatives and complexes thereof that retain heme-oxygenase inhibiting activity. Suitable dosage amounts are from 0.1 to 30 µmoles/kg of body weight of for example, a human. For example, where hemin (FePP) is used, suitable dosage amounts would be from about 0.06mg hemin to about 24 mg hemin per kilogram of body weight.

Alternative agents for induction or activation of heme-oxygenase are agents that inhibit or decrease nitric oxide synthesis. We have discovered a substantially reciprocal relationship between nitric oxide (NO) levels and heme-oxygenase activity wherein decreasing NO levels results in an increase in HO activity, and is anti-inflammatory. Thus, another embodiment of the first aspect of the invention is a pharmaceutical composition comprising, as an active ingredient, a substance that decreases NO levels, such as an inhibitor of nitric oxide synthetase (NOS).

According to a still further embodiment of the invention, a method of inducing (increasing) the level of heme-oxygenase in the body of a patient is provided, said method comprising administration of an effective dosage amount of heme-oxygenase inducer to reduce the inflammatory response in the patient.

In specific embodiments of the invention, inflammation is treated by inducing or stimulating a heme-oxygenase in mononuclear cells, such as in particular an inducible heme-oxygenase found in monocytes and macrophages. This is advantageous when treating chronic inflammation, typically medicated by and characterised by a large population of these cells at an inflammation site.

- 10 -

According to another embodiment of the invention, a method of controlling the inflammatory response in the human body is provided, said method comprising reducing the inflammatory response by administration of an effective dosage amount of heme-oxygenase inducer.

Preferably, the inducer is administered in a suitable pharmaceutically acceptable vehicle in any suitable manner (for example, sterile water, saline (sterile)). A buffered, isotonic aqueous solution having a pH of between about pH7 and pH8 is suitable. Lyophilised preparations are also be suitable. The lyophilised preparations may be reconstituted with sterile water.

In preferred embodiments of the invention, specifically chronic inflammation is treated. Diseases comprising chronic inflammation that can be treated according to the first aspects of the invention include chronic inflammatory joint disease - eg rheumatoid arthritis, chronic inflammatory bowel disease - eg Crohn's disease, respiratory inflammatory disease - eg asthma, chronic inflammation of the brain - eg multiple sclerosis, and inflammation of soft tissues - eg tendonitis.

According to another embodiment of the invention, a method of reducing the inflammatory response in the human body generally (treating inflammation) is provided, the method comprising monitoring the presence (expression) of HSP32 isoform of heme-oxygenase and, if decreased below normal level, administering an effective dosage amount of heme-oxygenase inducer to increase expression of the heme-oxygenase enzyme to thereby reduce the inflammatory response (inflammation). The inducer is preferably targeted at monocytes and macrophages.

Dosage amount(s) can be given over a period of time. However, the effects of compounds used to date appear to peak 24 hours after administration of each dosage amount and regress at 48 hours after administration.

- 11 -

The formulation can be in a unit dosage form (for one dosage) or may be packaged as a multiple formulation composition from which suitable dosage amounts can be extracted and used. For example, a solution in a vial may provide the multiple formulation composition from which the dosage amounts can be taken and administered. Compositions and uses of the first aspect of the invention are optionally supplemented by one or both of (1) a NSAID, and (2) a NOS (nitric oxide synthetase) inhibitor.

According to a second aspect of the invention, there is provided stimulation of an inflammatory response by inhibition or suppression of heme-oxygenase. In an embodiment of the second aspect, a pharmaceutical composition for stimulating or enhancing inflammation comprises a heme-oxygenase inhibitor and a pharmaceutically acceptable carrier.

The expressions "stimulate inflammation" and "enhance inflammation" are intended to indicate that at least one characteristic feature of inflammation is stimulated or enhanced; likewise the expressions "suppress inflammation", "decrease inflammation" and variants of all these expressions.

In treatment of immunosuppression using a composition according to the second aspect of the invention, for example treatment of AIDS, a heme-oxygenase inhibitor is administered to stimulate activity of monocytes and/or macrophages. These two cell types are crucial to fighting bacterial and viral infections, so increasing their activity offers a novel therapy, e.g. for AIDS sufferers.

Agents suitable for inhibiting heme-oxygenase (for example, inducible heme-oxygenase in monocytes and macrophages) are typically analogues of FePP (nb. which induces heme-oxygenase) in which the Fe ion is replaced by another metal ion, or the PP is replaced. Examples are:

SnPP	SnMP	SnDPP	CrPP	CrMP	CrDPP
ZnPP	ZnMP	ZnDPP	MnPP	MnMP	MnDPP

where:

- 12 -

Sn = tin, Cr-chromium, Zn = zinc, Mn = manganese, PP = protoporphyrin,
MP = mesoporphyrin and DPP = diiododeuteroporphyrin

Suitable dosage amounts of these agents would range from 0.1 to 50 μ moles/kg of body weight of for example, a human. For example, where tin protoporphyrin (SnPP) is used, suitable dosage amounts of SnPP would be from 0.07mg/kg to 46mg/kg of body weight of a human.

Antagonists of prostaglandin A receptors are further agents suitable for decreasing heme-oxygenase activity.

Alternative agents for reducing HO activity are agents that increase NO levels. Thus, another embodiment of the second aspect of the invention is a pharmaceutical composition comprising, as an active ingredient, a substance that increases the level of NO in a patient. The substance is, optionally, a substrate for nitric oxide synthetase (NOS) or a stimulator of this enzyme. A known substrate for NOS is L-arginine and a known NO donor is sodium nitroprusside.

According to another embodiment of the invention, a method of reducing the level of heme-oxygenase in the body is provided, said method comprising administration of an effective dosage amount of heme-oxygenase inhibitor to decrease the inflammatory response, for example, targeting an inducible heme-oxygenase found in monocytes and macrophages.

According to a further embodiment of the invention, a method of controlling the inflammatory response in the human body is provided, said method comprising activating the inflammatory response by administration of an effective dosage amount of heme-oxygenase inhibitor, for example, one that targets an inducible heme-oxygenase found in monocytes and macrophages.

The inhibitor can be administered in any suitable pharmaceutically acceptable

- 13 -

vehicle in any suitable manner (for example, sterile water, saline (sterile)). A buffered isotonic aqueous solution having a pH of between about pH7 and pH8 is suitable. Lyophilised preparations may also be suitable. The lyophilised preparations may be reconstituted with sterile water and administered.

According to another embodiment of the invention, a method of increasing an inflammatory response is provided (such as for a person suffering from AIDS), the method comprising monitoring the presence (expression) of HSP32 isoform of heme-oxygenase and, if increased above normal level, administering an effective dosage amount of heme-oxygenase inhibitor, thereby to increase the inflammatory response.

Dosage amount(s) can be given over a period of time. However, the effects of compounds used to date appear to peak 24 hours after administration of each dosage amount and regress at 48 hours after administration.

A still further embodiment of the invention is the use of a heme-oxygenase inhibitor in the manufacture of a medicament for treating immunosuppression. Another is the use of a heme-oxygenase inhibitor in the manufacture of a medicament for increasing the activity of monocytes and macrophages.

Immunosuppression can also be caused as a side effect of other therapies, for example post transplant immunosuppression due to drugs designed to suppress rejection of a transplanted organ. Rejection is largely mediated by a T cell response in these circumstances, so immunosuppression is to remove damaging T cell activity. However, a parallel loss of monocyte and macrophage activity (usually due to decreased numbers) is also seen. Thus, another use of the second aspect of the invention is the selective stimulation of monocytes and macrophages. By "selective" it is intended to indicate that activity and/or number of these cells is increased in higher proportion to any increase in activity and/or number of T cells.

- 14 -

The invention will now be illustrated in specific embodiments with reference to the figures in which:-

Figure 1 illustrates the development of an acute inflammation at 2, 6 and 24 hours after injection of carrageenin into the rat pleural cavity (open boxes - Cell exudate, closed boxes - Total cells, n = 6 each time point);

Figure 2 illustrates the measurement of HO activity as nmol bilirubin /60'/mg protein against time in hours during acute inflammation (n = 6 each time point);

Figure 3 is a photograph showing HSP detection by Western blot analysis, with a peak at 24 hours;

Figure 4 shows the development of acute inflammation in hours after injection of carrageenin into the rat pleural cavity (□ Exudate volume, ■ Total inflammatory cells, n = 10);

Figure 5 shows heme-oxygenase (HO) activity of inflammatory cells against time (hours) during carrageenin pleurisy, the activity is expressed as pmoles bilirubin/mg protein/hour, n = 9 (results are expressed as the mean \pm s.e.mean.
■ Peripheral blood mononuclear cells (PBMNs), □ Time course of inflammatory cells);

Figures 6 and 7 show Western blot analysis for heme-oxygenase isoforms:
Fig. 6) Analysis of inflammatory cell pellet for HO-1. Lanes, inflammatory cells taken at 2, 6, 12, 24 and 48 hours, spleen homogenate (SP), PBL (BL), Fig. 7)
Analysis of inflammatory cell pellet for HO-2. Lanes, inflammatory cells taken at 2, 6, 12, 24 and 48 hours, brain homogenate (BR), PBL (BL);

Figures 8-10 show immunolocalization of inflammatory cell smears for heme-oxygenase 1 confirming increased positive staining for heme-oxygenase-1 protein in mononuclear cells: Fig. 8) Normal rabbit serum (control), Fig. 9) 6

- 15 -

hour inflammatory cell smear, Fig. 10) 48 hour inflammatory cell smear;

Figures 11-16 show the effect of heme-oxygenase (HO) modulators on inflammation and HO activity: Effect of tin protoporphyrin dichloride (SnPP) on acute inflammation at 24 hours (Fig. 11 - exudate volume, Fig. 12 - cell number), Effect of ferriprotoporphyrin IX dichloride (FePP) on acute inflammation at 24 hours (Fig. 13 - exudate volume, Fig. 14. - cell number), Effect of SnPP (Fig. 15) and FePP (Fig. 16) administration on HO activity in 24 hour inflammatory cells, inflammatory cells were collected after treatment with the above porphyrins and HO activity measured as for Figure 5, $n=6$. * $P<0.05$, ** $P<0.01$ and *** $P<0.001$;

Figures 17 and 18 shows the effect of NG-nitro-L-arginine methyl ester (L-NAME) on rat brain and spleen heme-oxygenase activity, Fig. 17 - brain homogenates, Fig. 18 - spleen homogenates (0.1, 0.5, 1, 5 or 10mM of L-NAME was incubated with reaction mixture. Results are expressed as percentage activity of control (con) group which received no compound, $n=8$, *** $P<0.001$);

Figures 19 and 20 show the effect of L-arginine on rat brain and spleen heme-oxygenase activity, Fig. 19 - brain homogenates, Fig. 20 - spleen homogenates. 0.1, 0.5, 1, 5 or 10mM of L-arginine was incubated with reaction mixture. Results are expressed as percentage activity of control (con) group which received no compound, $n=8$, * $P<0.05$, *** $P<0.001$);

Figures 21 and 22 show the effect of D-arginine on rat brain and spleen heme-oxygenase activity, Fig. 21 - brain homogenates, Fig. 22 - spleen homogenates. 0.1, 0.5, 1, 5 or 10mM of D-arginine was incubated with reaction mixture, results are expressed as a percentage of control (con) group which received no compound, $n=8$); and

Figures 23 and 24 show the effect of sodium nitroprusside on rat brain and

- 16 -

spleen heme-oxygenase activity, Fig. 23 - brain homogenates, Fig. 24 - spleen homogenates. 0.001, 0.01, 0.1, 1 or 10mM sodium nitroprusside was incubated with reaction mixture, results are expressed as a percentage of control (Con) group which received no compound, $n=8$, * $P<0.05$, ** $P<0.01$, *** $P<0.001$.

Example 1

In the following example, we examined the expression and possible involvement of heme-oxygenase in acute and chronic inflammation. The highly inducible isoform of heme-oxygenase-1 has recently been classified as an HSP (HSP32). This is the rate limiting enzyme in the catabolism of the prosthetic group of heme proteins. The major product of this reaction, bilirubin, is a powerful free radical scavenger and may represent an endogenous mechanism by which cells protect themselves from free radical damage. Carbon monoxide (CO) is also produced by this reaction. Due to the structural similarities to nitric oxide a major mediator of inflammation, and the ability of both molecules to bind heme proteins the role of CO in inflammation raised an intriguing question for which we sought an answer.

In this embodiment, the rat carrageenin pleurisy model of acute inflammation has been used to determine the expression and activity of HSP32 in inflammatory cells. Markers of inflammation, cell exudate and cell number progressively increased over 2, 6 and 12 hours peaking at 24 and regressing at 48. The inflammation was dominated by polymorphonuclear leucocytes (PMNs) at the early time points, with an increase in the monocyte population as inflammation progressed. The increase in monocytes was associated with an increase in HSP32 protein levels determined by Western blot analysis, intensely labelled bands at 24 and 48 hours. Immunohistochemistry confirmed that HSP32 protein was present in monocytes. Heme-oxygenase (HO) activity was also assayed at 2, 6 and 24 hours, the later time point being the only one to show activity. The effects of modulating HO activity with hemin (an inducer of

- 17 -

HSP32 expression) and tin Protoporphyrin-IX (synthetic analogue of heme which inhibits HO activity) was then examined. The inducer or the inhibitor had no significant effect on inflammation at 6 hours compared to controls. However, at 24 hours the inhibitor significantly increased cell exudate by 135% ($p < .001$ Mann-Whitney), whereas the inducer of HSP32 decreased cell exudate and total cells by 83% ($p < .001$) and 50% ($p < .001$) respectively. The effects of these compounds thus corresponds to the temporal expression of HSP32 in this model of acute inflammation.

Materials and Methods

Animals & Drugs

Male Wistar rats 200 \pm 20 grams (Tuck & Sons Ltd., Essex, UK) were used for inflammation. Animals were administered either with 15mg/kg Ferriprotoporphrin IX chloride (FePP) by intravenous injection - 18 hours before inflammation or with 2 doses of 40 μ moles/kg Tin protoporphyrin dichloride (SnPP) by sub-cutaneous injection - 18 hours and at the time of inflammation induction (porphyrins were obtained from Porphyrin Products Inc., Logan, Utah). Drugs were prepared in 0.1N NaOH and mixed 1:1 with saline, these were then adjusted to pH 7.4, drug vehicle. The total volume injected was 0.2ml. Control animals received vehicle only.

Induction of Pleurisy

Carrageenin pleurisy was induced in rats and cell pellet prepared as previously described by Tomlinson et al.

HO Activity

HO Activity in the cell pellets was measured in post mitochondrial supernatant by quantifying the generation of bilirubin (Jollie DR et al, Arch Biochem Biophys, 1985, 240, pages 51-59), biliverdin reductase was substituted with rat hepatic cytosol (3mg/ml). Protein was estimated by the Bradford method using BSA as standard.

- 18 -

Western Blot Analysis

Cell pellets were lysed by the addition of protease inhibitory buffer containing 1% Triton X100 and boiled (10 min.) with gel loading buffer (Tris, 50mM; SDS, 10%; glycerol, 10%; 2-mercaptoethanol, 10% bromophenol blue, 2mg/ml) in a ratio of 1:1 and centrifuged at 10,000g, for 10 min. The protein concentrations of supernatants were determined as above, and total protein equivalents (20 μ g) for each sample separated on 10% sodium dodecyl sulfide-polyacrylamide mini-gels (Hoefer; Staffordshire, UK) using the Laemmli buffer system and transferred to polyvinylidene difluoride membranes (Millipore, Hertfordshire, UK). Non-specific IgGs were blocked with 5% dried milk protein and incubated with a polyclonal antibody to HSP32 1:1000 dilution (Stressgen Crop., Victoria, Canada). Bands were detected with an amplified alkaline phosphatase kit (Sigma Co. Poole, UK) and developed with nitroblue tetrazolium (NBT)-5-bromo-4-chloro-3-indonyl phosphate (BCIP). Rainbow marker and pre-stained blue protein markers were used for molecular weight determinations.

Statistics

Results are expressed as the mean \pm s.e. mean. Statistical analysis was determined by Mann-Whitney U-test, with a *P* value of <0.05 considered significant.

Figure 1 shows the development of exudate volume and cell number during inflammation in the pleural cavity; these were both maximal 24 hours after injection of the carrageenin. A significant increase in HO activity in the exudate cell pellet, Figure 2, and the detection of HSP32 protein by western blot analysis, Figure 2, and Figure 3 (photo), coincided with this peak in inflammation. The effects of the HO inhibitor SnPP and inducer FePP on carrageenin inflammation were then investigated (Table 1). Exudate volumes and cell numbers at 6 hours were not significantly modified by pre-treatment with HO inhibitor or inducer. However, 24 hours after initiation of the inflammation SnPP increased exudate volume by 128% as compared to vehicle control (*P*<0.001) whereas FePP decreased exudate volume by 73% and cell

- 19 -

number by 50% compared to vehicle control (both P<0.001).

The effect of heme-oxygenase inhibitor Tin protoporphyrin dichloride (SnPP) and inducer ferriprotoporphyrin IX chloride (FePP) on acute inflammation was examined. Treatment animals received either 2 doses of 40 μ moles/kg SnPP s.c. -18 and 0 hours before induction of inflammation, or 1 doses of 15mg/kg FePP i.v - 18 before inflammation. Treatment animals were compared to control animals which had received vehicle only by the appropriate route. ***P<0.001

These results demonstrate for the first time the induction of HSP32 expression and HO activity in inflammatory cells from a model of acute inflammation. The increase in HO activity reported above is associated with an increase in macrophages population in the pleural cavity. Immunohistochemistry demonstrated strong positive immunoreactivity of inflammatory macrophages but not peripheral monocytes for HSP32 in this model (data not given). The effect of pre-stimulating or inhibiting HO activity significantly decreases or increases inflammation respectively at 24 hours. This indicates that the major effect of HO modulators is on inflammatory macrophages at 24 hours, with no significant effect at 6 hours when the inflammatory site is dominated by polymorphonuclear leucocytes. An increase in HO activity achieved by the invention represents a novel therapy for the treatment of chronic inflammatory disease and, conversely, a decrease in activity will be of benefit in those individuals with an impaired inflammatory response.

Example 2

Methods

Drugs Administration

Animals received 2 doses of either 3, 10 or 30 μ moles/kg SnPP (a HO inhibitor) or vehicle control -18 hours and at the time of inflammation induction. Animals received 1 dose of either 3, 10 or 30 μ moles/kg FePP (a HO inducer) or vehicle control -18 hours before induction of inflammation, n=9.

- 20 -

Induction of pleurisy.

Male Wistar rats 200 + 20 grams were anaesthetized with halothane and 150ul of a 1% carrageenin solution in 0.9% NaCl injected into the pleural cavity. Exudates were collected 2, 6, 12, 24 and 48 hours after injection of the irritant by pleural lavage with 1ml protease inhibitory buffer containing: trisodium citrate 3.15%, phenylmethylsulfonyl fluoride 1mM (Sigma Chemical Co., Poole, UK), pepstatin A 1.5mM (Sigma) and leupeptin 0.2mM (Sigma) in 10mM phosphate buffered (PBS) pH 7.3 . Any exudates with blood contamination were rejected. Cells were counted using a Coulter counter, model DN (Coulter Electronics Ltd., Luton, UK). Each sample was centrifuged at 800g for 10 minutes and the resultant cell pellet prepared as outlined below.

Immunohistochemistry.

Peripheral blood and exudate cell samples were smeared onto poly-L-lysine coated slides and allowed to air dry. Prior to immunolabelling or histological staining, smears were fixed in 4% paraformaldehyde in 0.1M phosphate buffer for 1 hour. Endogenous peroxidase were quenched with 0.3% H₂O₂ in methanol and sections washed with 0.1% Triton X100 in PBS. Non-specific binding of IgGs was blocked using NGS 1:50 in 0.1% essentially globulin free BSA in PBS. The sections were incubated overnight with polyclonal anti-HO-1 (1:200) or polyclonal anti-HO-2 (1:1000) at 4°C, washed and incubated for a further 30 minutes with biotinylated goat anti-rabbit secondary antibody. Following a further 30 minutes incubation with Vectastain ABC horseradish-peroxidase (Vector Labs, Peterborough, UK), the substrate 0.05% diaminobenzidine tetrahydrochloride (Sigma) in 0.05M Tris buffer pH 7.6 was added for the appropriate time period (5-10 mins). This resulted in positive immunoreactivity labelling brown. Primary antiserum was replaced with NGS, as a negative control. Morphological observations were confirmed using the routine histological stain, haematoxylin and eosin.

Statistics

Results are expressed as the mean ± s.e.mean for (n) experiments. Statistical

- 21 -

analysis was determined Student's unpaired *t* test, with a *P* value of <0.05 considered significant.

Heme-oxygenase Assay

HO activity is assessed as previously described by Sierra ES et al, *Anal. Biochem.* 1992; 200:27-30. Cells are lysed by sonication for 10 seconds in protease inhibitory buffer. Heme-oxygenase is assayed as previously described. The reaction mixture (15 μ l) consists of 11.2 μ M [14 C] heme specific activity 54 Ci/mol), 1mM NADPH, 2mM glucose-6-phosphate, 0.1 units of glucose-6-phosphate dehydrogenase, 3mg/ml liver cytosolic protein and 50-100 μ g of sample protein. The reaction is started by the addition of the heme, incubated at 37°C for 30 minutes and stopped by the addition of excess cold heme and bilirubin followed by placing on ice. 2 μ l of reaction mixture is spotted twice onto a silica gel thin-layer chromatography sheet. The chromatogram is developed using a 20:1 dilution of chloroform:acetic acid. Spots corresponding to hem and bilirubin are cut out and placed in 10ml of scintillation fluid to be counted. Protein determination were carried by the Bradford method (Bradford MM et al *Anal. Biochem.* 1976; 72:248-254), BSA was used as protein standard. The activity is expressed as pmoles bilirubin/mg protein/hour, n=9. Results are expressed as the mean \pm s.e.mean.

Results

Injection of carrageenin into the pleural cavity of a rat resulted in the development of an acute pleurisy which was maximal at 24 hours as assessed by inflammatory cell number and exudate volume (Fig 4). At 48 hours the inflammatory lesion had virtually resolved, with cell number and exudate volume reduced to 25% and 11% respectively of levels seen when inflammation was maximal. The early part of the inflammation was characterised by influx of polymorphonuclear cells (PMNs) into the pleural cavity, with an increasing percentage of mononuclear cells (MNs) occurring at 24 and 48 hours [Table 2]. HO activity dramatically increased as the inflammation progressed, the highest activity being recorded when the inflammation was resolving (Fig 4) when MNs

- 22 -

dominated the inflammatory lesion. Western blot analysis confirmed that there was a dramatic increase in HO-1 protein levels (data not shown). In inflammatory cell smears HO-1 immunoreactivity was specifically localized to mononuclear cells with PMNs showing little or no staining. The number of positively stained cells increased as the inflammation progressed (Figs. 8-10). A similar staining profile with immunoreactivity being localised to mononuclear cells was observed with polyclonal antibodies to HO-2.

These results indicated that there is an increase in HO expression and activity in inflammatory cells. To investigate whether increased HO activity was not only associated with tissue protection but also involved in resolving acute inflammation we used an HO inhibitor, tin protoporphyrin (SnPP), administered sub-cutaneously 18 hours before and at the time of carrageenin injection, and an HO inducer, ferriprotoporphyrin IX chloride (FePP), given sub-cutaneously 18 hours before induction of the inflammation (Maines MD et al., *FASEB J.* 1988; 2:2557-2568).

Neither SnPP or FePP treatments had an effect on the inflammatory lesion as compared to vehicle control 6 hours after injection of the carrageenin, the PMNs phase of inflammation, (data not shown). However, 24 hours after injection of carrageenin, when there was a dominance of MNs, animals receiving SnPP (the HO inhibitor) showed a dose dependant increase in inflammatory exudate, with animals dosed 3 μ moles/kg SnPP increasing exudate volume by 70% compared to vehicle control (Fig 11). It was noted that the highest dose of SnPP (30 μ moles/kg) increased exudate volume further but resulted in a decrease in inflammatory cell number (Fig. 12), the likely explanation the later being a toxic effect. In contrast, animals receiving FePP, the HO inducer, showed a dose dependant suppression of inflammatory cell number and exudate volume (Fig 13 and Fig. 14), all the dosages used significantly reduced inflammation with the lowest dose of FePP (3 μ mole/kg) reducing inflammatory cell number and exudate volume by 90% and 55% respectively compared to vehicle control.

- 23 -

The degree of suppression achieved is greater than that seen with optimal doses of conventional anti-inflammatories or steroids in this model. Analysis of the inflammatory pellets for HO activity confirmed reduction of HO activity with SnPP and increase after treatment with FePP (Fig 15 and 16). These finding would support the idea of HO activity being important in the resolution of acute inflammation. The data would also suggest that the main mode of action of SnPP and FePP is via modulation of HO activity and not other mechanisms, as the phenomena appears dose dependant, and the opposing effects of the porphyrins is only observed when HO is expressed.

In conclusion, the findings of this example implicate a direct involvement of HO in the resolution of acute inflammation. The presence of HO in the MNs, a cell type closely associated with chronic inflammation, would support the concept of this enzyme as a modulator of the chronic inflammatory response, and therefore a target for therapies according to the various aspects of the present invention.

Example 3

Methods

The brains and spleens of male Wistar rats ($160 \pm 20\text{g}$, Tuck Co. UK) were homogenised using a glass homogenizer, in protease inhibitory buffer; phenylmethylsulfonyl fluoride 1mM, pepstatin A 1.5mM and leupeptin 0.2mM, in 10mM phosphate buffered saline pH 7.3. Protein determinations were carried by the Bradford method, bovine serum albumin was used as protein standard.

Nitric oxide synthase activity was determined by the citrulline assay and the data calculated as pmol citrulline/mg protein/30min (Vane, J.R. et al (1993) Proc. Natl. Acad. Sci. USA 91, 2046-2050).

Heme-oxygenase activity was assayed as previously described (Sierra, E.E. et al, (1992) Analytical Biochem. 200, 27-30).

Briefly, the $15\mu\text{l}$ reaction mixture consisted of $11.2\mu\text{M}$ [^{14}C] heme (specific

- 24 -

activity 54 Ci/mol), 1mM NADPH, 2mM glucose-6-phosphate, 0.1 units of glucose-6-phosphate dehydrogenase, 3mg/ml liver cytosolic protein, 100-50 μ g of sample protein and the relevant concentration of test drugs; L-arginine, D-arginine, NG-nitro-L-arginine methyl ester (L-NAME) or sodium nitroprusside. The reaction mixture containing the test drugs was allowed to equilibrate at 37°C for 15 mins before the reaction was started by the addition of the heme. The reaction was terminated after 30 mins by the addition of excess cold heme and bilirubin and placed on ice. The reaction mixture was spotted on to the silica gel thin-layer chromatography sheet by 2, 2 μ l applications. All samples were run in duplicate. The chromatogram was developed using a 20:1 dilution of chloroform:acetic acid. Spots corresponding to heme and bilirubin were excised and placed in 10ml of scintillation fluid to be counted. The data was calculated as pmols bilirubin formed/mg protein/hour.

Statistical analysis of the raw data was carried using Student's unpaired t test. Results expressed as mean \pm s.e.mean with $P < 0.05$ considered as significant.

Results

Homogenates of rat brain contained both HO and NOS activity as determined by our assay systems. In comparison, rat spleen homogenates had double the HO activity, but lacked NOS activity (Table 3). Addition of the NOS inhibitor, L-NAME, resulted in a dose dependent increase in brain HO activity, with 5mM L-NAME significantly increasing activity by 80% (Figure 17). Conversely, addition of L-arginine, the NOS substrate, to brain homogenates, resulted in a dose dependent decrease in HO activity (Figure 19). The highest concentration of L-arginine used, 10mM, reduced HO activity by 75%. The enantiomer of L-arginine, D-arginine, which cannot be utilised as a substrate by NOS, had no significant effect on brain HO activity (Figure 21).

Spleen HO activity, unlike brain activity was not modified by the addition of L-NAME, L-arginine or D-arginine (Figure 18, 20 and 22 respectively). However the addition of the NO donor sodium nitroprusside resulted in a dose dependent

- 25 -

decrease in HO activity in both spleen and brain homogenates (Figures 23 and 24). The addition of 10mM sodium nitroprusside resulted in a 75% and 80% decrease in the HO activity of brain and spleen homogenates respectively.

These results demonstrate that NO, generated by NOS, inhibits HO activity. It is important to note that the isoforms of NOS and HO present in the brain under normal physiological conditions are the constitutive forms of the enzymes, cNOS and HO-2 respectively (Bredt, D.S. et al, (1990) Proc. Natl. Acad. Sci. USA 87, 682-685, and Verma, A., et al, (1993) Science 259, 381-384); whereas spleen under normal physiological conditions contains only the inducible form of HO (Maines, M.D. (1988) FASEB J. 2,2557-2568).

The effects of inhibitors and donors of NO on HO activity have been examined in homogenates of rat brain, where endogenous activity of both NOS and HO are high and in rat spleen where HO is higher, but NOS activity lower than in brain.

We have found that a substrate for nitric oxide, L-arginine (0.1-10mM), but not D-arginine, decreased heme-oxygenase activity in rat brain homogenates and that the arginine analogue L-NAME (0.1-10mM) increased activity in the same tissue. In spleen homogenates where endogenous nitric oxide activity is lower than in brain, these compounds had no effect. The nitric oxide donor sodium nitroprusside (0.001mM-10mM) reduced heme-oxygenase activity in both brain and spleen.

It is believed by the inventors that in conditions where NOS is induced, the effect of NO modulation of HO activity would be amplified. Further, it is suggested that NO modulates production of the important inflammatory mediators the prostanoids, by its interaction with the heme-containing enzyme cyclo-oxygenase. We have demonstrated an anti-inflammatory role for HO in a model of inflammation. We suggest that NOS and HO have reciprocal modulatory effects in inflammation which effects are the basis for the various aspects of the present invention.

- 26 -**Table 1**

Treatment Groups	Exudate Volume (ml)	Total Cells 10^6
6 hours		
Vehicle injected s.c (n = 27)	1.26 \pm 0.10	72 \pm 7
SnPP injected s.c (n = 26)	1.59 \pm 0.12	67 \pm 6
Vehicle injected i.v. (n = 23)	1.29 \pm 0.15	69 \pm 8
FePP injected iv.v (n = 26)	0.99 \pm 0.11	50 \pm 8
24 hours		
Vehicle injected s.c (n = 29)	0.79 \pm 0.12	63 \pm 6
SnPP injected s.c (n = 24)	1.80 \pm 0.21	58 \pm 6
Vehicle injected i.v. (n = 22)	1.37 \pm 0.16	90 \pm 6
FePP injected iv.v (n = 25)	0.37 \pm 0.07	45 \pm 6

Table 2

Time	Cell type	% of total cell number*	% +ve for HO-1*	% +ve for HO-2*
2 hours	PMNs	86	0	0
	MNs	14	25	45
6 hour	PMNs	>99	0	0
	MNs	<1	N.D.	N.D.
12 hours	PMNs	>99	0	0
	MNs	<1	N.D.	N.D.
24 hours	PMNs	62	0	0
	MNs	38	36	41
48 hours	PMNs	30	0	0
	MNs	70	89	46

Immunocytochemical analysis of inflammatory cell smears.

* Relative percentage of polymorphonuclear cells (PMNs) and mononuclear cell (MNs) in inflammatory cell smear. * Percentage of PMNs and MNs present, which are positive for heme-oxygenase isoforms. N.D. insufficient cells present for analysis.

- 28 -**Table 3**

	brain <i>n=8</i>	spleen <i>n=5</i>
Heme-oxygenase activity pmol bilirubin/mg protein/30'	40±4	85±5
nitric oxide synthase activity pmol citrulline/mg protein/30'	358±78	2.38±1

Heme-oxygenase and nitric oxide synthase activity in rat brain and spleen homogenates. Mean \pm s.e.mean.

Thus, control of inflammation according to the invention is achieved, in embodiments of the invention, by (1) control of HO, or (2) control of levels of nitric oxide, alone or in combination with control of HO.

As many changes can be made to the embodiment of the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.

- 29 -

CLAIMS

1. Use of a compound that alters activity, or amount, of heme-oxygenase in a mammal, in the manufacture of a medicament for control of inflammation.
2. Use according to Claim 1 of a compound that increases heme-oxygenase activity in the manufacture of a compound for the treatment of inflammation.
3. Use according to Claim 2 of a compound that induces heme-oxygenase.
4. Use according to Claim 2 of a compound that decreases nitric oxide levels.
5. Use according to Claim 4 of a nitric oxide synthetase inhibitor.
6. A pharmaceutical composition for the treatment of inflammation, said composition comprising a compound that increases heme-oxygenase activity, wherein said composition is in the form of a tablet, a pill, a powder for suspension in aqueous solution, a powder for dissolution in aqueous solution, a topical preparation further comprising an oil, a wax, a gel, a cream or an emulsion, or is a sterile aqueous solution for injection.
7. A pharmaceutical composition according to Claim 6 comprising a compound that increases heme-oxygenase activity selected from a prostaglandin of the A series; an agonist of a prostaglandin A receptor; vitamin B₁₂; hemin; and a fragment, sub-unit, conjugate, analogue, derivative or complex of hemin retaining heme-oxygenase inducing activity.
8. A pharmaceutical composition according to Claim 6 or 7 further comprising a taste enhancing agent and being for oral administration.

- 30 -

9. Use of a compound that increases heme-oxygenase activity in the manufacture of a medicament for treatment of chronic inflammation.
10. Use of a compound that increases heme-oxygenase activity in the manufacture of a medicament for treatment of a disease selected from rheumatoid arthritis, a chronic inflammatory bowel disease, multiple sclerosis, asthma, airways inflammatory disease, tendonitis and chronic inflammation in the brain.
11. Use according to Claim 1 of a compound that decreases heme-oxygenase activity in the manufacture of a medicament for stimulating an inflammatory response.
12. Use according to Claim 11 of a heme-oxygenase inhibitor.
13. Use according to Claim 12 wherein the heme-oxygenase inhibitor is an analogue of FePP.
14. Use according to Claim 13 wherein the analogue is selected from SnPP, SnMP, SnDPP, CrPP, CrMP, CrDPP, ZnPP, ZnMP, ZnDPP, MnPP, MnMP, MnDPP, wherein PP equals protoporphyrin, MP equals mesoporphyrin and DPP equals diiododeuteroporphyrin.
15. Use according to Claim 11 of a compound that increases nitric oxide levels.
16. Use according to any of Claims 11-15 in the manufacture of a medicament for treatment of immunosuppression.
17. Use according to Claim 16 in the manufacture of a medicament for treatment of AIDS.

- 31 -

18. Use according to any of Claims 11-17 in the manufacture of a medicament for stimulation of mononuclear cells.
19. A pharmaceutical composition comprising a compound that increases levels of nitric oxide.
20. A pharmaceutical composition according to Claim 19 comprising a substrate for nitric oxide synthetase or a nitric oxide donor.
21. A method of controlling inflammation in a patient comprising administration of a pharmaceutical composition that alters the activity of heme-oxygenase.
22. A method according to Claim 21 for reducing inflammation comprising administration of a compound that increases heme-oxygenase activity or increases heme-oxygenase levels.
23. A method according to Claim 22 comprising administration of a heme-oxygenase inducer.
24. A method according to Claim 21 or 22 comprising administration of a prostaglandin A receptor agonist.
25. A method according to Claim 21 for stimulation of an inflammatory response comprising administration of a compound that decreases heme-oxygenase activity.
26. A method according to Claim 25 comprising administration of a compound that increases levels of nitric oxide.
27. A method according to Claim 25 comprising administration of a heme-oxygenase inhibitor.

- 32 -

28. A method according to Claim 27 comprising administration of an analogue of FePP, wherein the analogue inhibits heme-oxygenase.
29. A method according to any of Claims 25-28 for the treatment of immunosuppression, such as seen in AIDS.

1 / 9

FIG. 1





FIG. 2



2 / 9

FIG. 3






FIG. 4



3 / 9



4 / 9

FIG. 6





FIG. 7



5/9




FIG. 8




FIG. 9



FIG. 10

6 / 9

FIG. 11




FIG. 12




FIG. 13





FIG. 14



7/9

FIG. 15




FIG. 16




FIG. 17





FIG. 18



8 / 9

FIG. 19




FIG. 20




FIG. 21





FIG. 22



9 / 9

FIG. 23





FIG. 24



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00, 31/40, 31/557, 31/68 A61K 31/195, 33/26	A3	(11) International Publication Number: WO 96/09038 (43) International Publication Date: 28 March 1996 (28.03.96)
(21) International Application Number: PCT/GB95/02249		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date: 22 September 1995 (22.09.95)		
(30) Priority Data: 2,132,690 22 September 1994 (22.09.94) CA		
(71) Applicant (for all designated States except US): WILLIAM HARVEY RESEARCH LIMITED [GB/GB]; Saint Bartholomew and the Royal London Hospital School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ (GB).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors; and		
(75) Inventors/Applicants (for US only): WILLIS, Dean [GB/GB]; 16 Croft Road, Atherstone, Warwickshire CV9 1HQ (GB). MOORE, Adrian, Richard [GB/GB]; 101 Windsor Road, Ilford, Essex IG1 1HG (GB). WILLOUGHBY, Derek, Albert [GB/GB]; 83 Bow Lane, Finchley, London N12 0JL (GB).		(88) Date of publication of the international search report: 13 June 1996 (13.06.96)
(74) Agent: SCHLICH, George, William; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).		

(54) Title: **ALTERATION OF ACTIVITY AND/OR LEVELS OF HAEM-OXYGENASE TO CONTROL INFLAMMATION**

(57) Abstract

Control of inflammation is achieved by control of the level and/or activity of the enzyme heme-oxygenase (HO). A HO inducer is anti-inflammatory (figure 14) and used to treat inflammation, such as chronic inflammatory diseases. A HO inhibitor promotes inflammation and is used to treat immunosuppressed conditions. Alternative, or additional, control of heme-oxygenase activity is achieved by control of nitric oxide levels, elevated levels promoting inflammation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/95/02249

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/00 A61K31/40 A61K31/557 A61K31/68 A61K31/195
A61K33/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOCHEM J., vol. 279, no. pt 3, 1991 pages 891-894, L. CANTONI ET AL. 'Interleukin-1 and tumor necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids.' see the whole document ---	1,2,6, 21-23
X	GB,A,2 263 111 (S.C.R.A.S) 14 July 1993 see page 2 - page 3 ---	1,4-6
X	WO,A,93 13055 (WELLCOME FOUNDATION) 8 July 1993 see page 5; claim 1 ---	1,4-6
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- '&' document member of the same patent family

4

Date of the actual completion of the international search

29 March 1996

Date of mailing of the international search report

29.04.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/GB 95/02249

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 13252 (HEMOGEN INC.) 23 June 1994 see page 3; claims ---	1,2,6,7, 21-23
X	WO,A,92 18112 (CHILDREN'S MEDICAL CENTER CORP.) 29 October 1992 see claims ---	19,20
X	WO,A,93 07114 (USA DEPT. HEALTH AND HUMAN SERVICES) 15 April 1993 see page 25; claims ---	19,20
A	WO,A,91 04667 (ROCKEFELLER UNIVERSITY) 18 April 1991 -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB95/02249

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1 (partially), 2-10, 21-24
2. Claims 1 (partially), 11-20, 25-29

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

LACK OF UNITY OF INVENTION

The aim of the present application is to provide a novel use for known compounds. This use consists of the alteration of the activity or amount of heme-oxygenase in order to control inflammation. Both induction and inhibition of heme-oxygenase can be useful within the inventive concept.

As can be learned from Biochem. J. 1991.279/pt.3, pages 891-4, heme-oxygenase can be induced in vivo by the administration of interleukin-1 or TNF in inflammatory conditions.

The conclusion is that the alteration of heme-oxygenase activity in the sense of the invention is not novel. This means there is no single unifying concept linking the different aspects of the invention as a result of which the application lacks unity of invention a posteriori.

In the present application no further technical feature(s) can be distinguished that can be regarded as a "special technical feature" involved in the technical relationship among the different inventions.

Consequently, the present application lacks unity of invention, and the different solutions not belonging to a common inventive concept are identified as the different subjects listed in the communication pursuant to Article 17(3)(a)PCT. Each of the inventions listed is a distinct invention, characterised by its own special technical feature, defining the contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Searching these different subjects would have caused major additional searching efforts. Only the first subject was searched.

1. Claims: 1 (partly), 2-10, 21-24 Use of a compound to increase or induce heme-oxygenase levels or activity for the control of inflammation
2. Claims: 1 (partly), 11-20, 25-29 Use of a compound to reduce heme-oxygenase levels or activity for the control of inflammation

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/95/02249

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-2263111	14-07-93	AT-A-	256092	15-10-95
		AU-B-	664399	16-11-95
		AU-B-	3049892	08-07-93
		BE-A-	1006227	14-06-94
		CA-A-	2085555	05-07-93
		CH-A-	685629	31-08-95
		DE-A-	4244539	08-07-93
		ES-A-	2052452	01-07-94
		FR-A-	2685869	09-07-93
		FR-A-	2685916	09-07-93
		GR-B-	1001443	30-12-93
		IT-B-	1256761	15-12-95
		JP-A-	5286916	02-11-93
		LU-A-	88208	15-04-93
		NL-A-	9300001	02-08-93
		NZ-A-	245499	26-07-95
		PT-A-	101165	28-02-94
		SE-A-	9203825	05-07-93
		US-A-	5360925	01-11-94
		US-A-	5480999	02-01-96
		ZA-A-	9210080	02-08-93
-----	-----	-----	-----	-----
WO-A-9313055	08-07-93	AU-B-	3169293	28-07-93
		EP-A-	0618898	12-10-94
		HU-A-	70502	30-10-95
		JP-T-	7502512	16-03-95
		ZA-A-	9210018	23-06-94
-----	-----	-----	-----	-----
WO-A-9413252	23-06-94	AU-B-	5747294	04-07-94
		CA-A-	2151148	23-06-94
		EP-A-	0673236	27-09-95
-----	-----	-----	-----	-----
WO-A-9218112	29-10-92	EP-A-	0581856	09-02-94
		JP-T-	6506690	28-07-94
		US-A-	5455279	03-10-95
		US-A-	5234956	10-08-93
-----	-----	-----	-----	-----
WO-A-9307114	15-04-93	AU-B-	2669092	03-05-93
		CA-A-	2119572	15-04-93
		EP-A-	0605622	13-07-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/B 95/02249

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9307114		JP-T- 7502265	09-03-95	
		US-A- 5366997	22-11-94	
-----	-----	-----	-----	-----
WO-A-9104667	18-04-91	US-A- 5010073	23-04-91	
		AU-B- 634299	18-02-93	
		AU-B- 6544090	28-04-91	
		CA-A- 2042576	06-04-91	
		EP-A- 0446340	18-09-91	
		JP-T- 4502019	09-04-92	
-----	-----	-----	-----	-----